Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today anno...
Gainers: Cleveland BioLabs (CBLI) +96%, Anchiano Therapeutics (ANCN) +46%, Aptinyx (APTX) +45%, SOS (SOS) +21%, Liquidia Technologies (LQDA) +18%.Losers: Baudax Bio (BXRX) -37%, BOQI International Medical (BIMI) -13%, Midatech Pharma (MTP) -11...
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...
Calithera initiates Phase 2 trial for lung cancer treatment. Vertex receives FDA approval for cystic fibrosis treatment. IGM Biosciences makes a deal with AbCellera for antibody discovery. For further details see: Calithera Lung Cancer Trial, And Other News: The Good, Ba...
Calithera Biosciences (CALA) has commenced Phase 2 (KEAPSAKE) trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with pembrolizumab, carboplatin and pemetrexed.The 120-subject study will evaluate the safety and investigator-assessed progression-free survival of...
- Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard - of - care treatment in front-line setting among patients with non-small cell lung cancer and a mutation in the KEAP1 /NRF2 pathway ...
Calithera signals terminating partnership with Incyte Calithera Biosciences Inc. ( CALA ) reported that it has sent a written intimation to Incyte ( INCY ) terminating their collaboration and licensing agreement. The termination will be effective from September 30. The companies had entere...
Calithera Biosciences (NASDAQ: CALA ) discloses that it has delivered written notice to Incyte (NASDAQ: INCY ) terminating their January 2017 collaboration and license agreement effective September 30. More news on: Calithera Biosciences, Inc., Incyte Corporation, Healthcare stocks...
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...
Image source: The Motley Fool. Calithera Biosciences Inc (NASDAQ: CALA) Q2 2020 Earnings Call Aug 10, 2020 , 5:00 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
OTCMKTS Market:
Calithera Biosciences Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...